Alkermes plc. Contract with Customer, Asset, Allowance for Credit Loss
Alkermes plc. (ALKS) had Contract with Customer, Asset, Allowance for Credit Loss of $400.00 thousand as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Balance Sheet › Assets › Contract with Customer, Asset, after Allowance for Credit Loss
us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss · last filed 2026-02-25
- 2025-12-31: Contract with Customer, Asset, Allowance for Credit Loss $400.00K.
- 2024-12-31: Contract with Customer, Asset, Allowance for Credit Loss $300.00K.
- 2023-12-31: Contract with Customer, Asset, Allowance for Credit Loss $200.00K.
- 2022-12-31: Contract with Customer, Asset, Allowance for Credit Loss $200.00K.
| Period end | Contract with Customer, Asset, Allowance for Credit Loss |
|---|---|
| 2025-12-31 | $400.00K 10-K · filed 2026-02-25 |
| 2024-12-31 | $300.00K 10-K · filed 2026-02-25 |
| 2023-12-31 | $200.00K 10-K · filed 2025-02-12 |
| 2022-12-31 | $200.00K 10-K · filed 2024-02-21 |
| 2021-12-31 | $200.00K 10-K · filed 2023-02-16 |
| 2020-12-31 | $100.00K 10-K · filed 2022-02-16 |
| 2019-12-31 | $200.00K 10-K · filed 2021-02-11 |
| 2018-12-31 | $200.00K 10-K · filed 2020-02-13 |
| 2018-09-30 | $200.00K 10-Q · filed 2018-10-23 |
| 2018-06-30 | $200.00K 10-Q · filed 2018-07-26 |
| 2018-03-31 | $200.00K 10-Q · filed 2018-04-26 |
| 2017-12-31 | $200.00K 10-K · filed 2019-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |